ZEMDRI Drug Patent Profile

When do Zemdri patents expire, and what generic alternatives are available?

Zemdri is a drug marketed by Cipla Usa and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-eight patent family members in twenty-one countries.

The generic ingredient in ZEMDRI is plazomicin sulfate. Three suppliers are listed for this compound. Additional details are available on the plazomicin sulfate profile page.

DrugPatentWatch^® Generic Entry Outlook for Zemdri

Zemdri was eligible for patent challenges on June 25, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 25, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZEMDRI

International Patents:	28
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	16
Clinical Trials:	1
Patent Applications:	1
Drug Prices:	Drug price information for ZEMDRI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZEMDRI
DailyMed Link:	ZEMDRI at DailyMed

See drug prices for ZEMDRI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZEMDRI

NDA:

210303

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZEMDRI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cipla USA Inc.	Phase 1

See all ZEMDRI clinical trials

US Patents and Regulatory Information for ZEMDRI

ZEMDRI is protected by four US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cipla Usa	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		RX	Yes	Yes				Y
Cipla Usa	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		RX	Yes	Yes			Y
Cipla Usa	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		RX	Yes	Yes
Cipla Usa	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		RX	Yes	Yes				Y
Cipla Usa	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		RX	Yes	Yes
Cipla Usa	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		RX	Yes	Yes

International Patents for ZEMDRI

When does loss-of-exclusivity occur for ZEMDRI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hungary

Israel

Japan

Lithuania

Mexico

Poland

Portugal

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZEMDRI around the world.

Country	Patent Number	Title	Estimated Expiration
Croatia	P20170154
Slovenia	2217610
China	101868472
World Intellectual Property Organization (WIPO)	2009067692
South Korea	20100110297	ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS
European Patent Office	3150617	ANALOGUES D'AMINOGLYCOSIDES ANTIBACTÉRIENS (ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS)

Market Dynamics and Financial Trajectory for ZEMDRI (delafloxacin)

Last updated: January 11, 2026

Summary

ZEMDRI (delafloxacin) is a broad-spectrum fluoroquinolone antibiotic developed by Melinta Therapeutics, primarily indicated for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). As the landscape of antibiotic development shifts amid rising antimicrobial resistance (AMR), ZEMDRI occupies a strategic niche due to its enhanced efficacy, tissue penetration, and activity against resistant pathogens.

This analysis explores the current market environment, competitive positioning, regulatory considerations, and financial outlook for ZEMDRI from 2023 onward. It covers key drivers shaping its market trajectory, potential bottlenecks, revenue projections, and strategic imperatives for stakeholders.

---

1. Introduction to ZEMDRI and Its Clinical Profile

Attribute	Details
Generic Name	Delafloxacin
Brand Name	ZEMDRI
Developer	Melinta Therapeutics (acquired rights from Melinta in 2020)
Indications	ABSSSI, CABP
Approval	FDA approved in June 2017
Delivery	Intravenous (IV), Oral formulations

Clinical Advantages:

• Broad-spectrum activity against Gram-positive and Gram-negative bacteria, including MRSA.
• Acidic environment efficacy superior to other fluoroquinolones.
• Less collateral damage to gut microbiome.
• Once-daily dosing with an advantage in outpatient management.

---

2. Market Dynamics: Drivers and Restraints

What Are the Key Drivers of ZEMDRI’s Market?

Driver	Impact	Supporting Evidence
Antimicrobial Resistance (AMR)	Accelerates demand for new antibiotics effective against resistant strains like MRSA.	WHO 2019 prioritized development of novel antibiotics [1].
Unmet Medical Need	Limited options for complicated skin infections, particularly resistant strains.	CDC reports increasing MRSA prevalence in SSTIs (~50%) [2].
Regulatory Backing	FDA’s encouragement for new antibiotics via incentives (QIDP, Fast Track).	ZEMDRI received QIDP designation for certain indications.
Shift toward Outpatient Therapy	Oral formulation supports outpatient management, reducing hospitalization costs.	CMS incentives favor oral antibiotics where appropriate.
Pricing & Reimbursement	Price premium justified by efficacy and resistance profile.	Approximate price per IV dose (~$1000).

What Restraints Impede ZEMDRI’s Growth?

Restraint	Impact	Evidence
Generic Competition	Several generics for older fluoroquinolones remain price crushers.	Ciprofloxacin, levofloxacin (generic) dominate market.
Limited Indication Expansion	Currently approved only for ABSSSI and CABP limits revenue avenues.	No approval for urinary tract infections or other off-label uses.
Market Penetration Challenges	Competing against established antibiotics with strong hospital and outpatient adherence.	Existing drugs like vancomycin, linezolid, levofloxacin.
Safety Concerns	Fluoroquinolones face scrutiny over side effects; limits prescription.	FDA boxed warnings for tendinitis, neuropathy, CNS effects.
Supply & Manufacturing Issues	Past manufacturing challenges affected supply chain stability.	Melinta’s bankruptcy in 2019 impacted sales efforts.

---

3. Competitive Landscape Analysis

Competitors	Market Share	Strengths	Weaknesses
Vancomycin	Dominant in MRSA SSTIs	Well-established, Cost-effective	IV-only, nephrotoxicity risks
Linezolid (Zyvox)	Significant in MRSA, VRE	Oral availability	Cost, hematologic toxicity
Levofloxacin, Ciprofloxacin	Broad spectrum	Oral, inexpensive	Resistance, safety concerns
Delafloxacin (ZEMDRI)	Niche position	Effective against resistant strains, oral IV	Limited indications, competition from generics

Market Share Overview (2022):

Antibiotic	Estimated Market Share	Key Use Cases
Vancomycin	~40%	MRSA SSTIs
Linezolid	~20%	VRE, MRSA
Levofloxacin	~15%	Pneumonia, SSTIs
ZEMDRI	~3-5%	Niche resistant infections

---

4. Regulatory and Policy Environment

FDA Stance & Incentives

• Fast Track & QIDP Designations: Facilitate expedited review and development credits.

• Post-Approval Commitments: Ongoing Phase 4 studies on resistance patterns and safety.

Insurance & Reimbursement Patterns

• Coverage Trends: Favor outpatient oral antibiotics to reduce hospital costs.
• Pricing Policies: Payers scrutinize high-cost antibiotics; value-based pricing models emerging.

---

5. Financial Trajectory Analysis

Historical Financials and Revenue

Year	Revenue (USD in millions)	Notes
2017	~$20	Post-approval sales initiation
2018	~$15	Limited penetration, manufacturing issues
2019	~$10	Continued struggles, patent expiry fears
2020	(~$2)	Acquisition by Melinta; restructuring

Projected Revenue Roadmap (2023 – 2027)

Year	Estimated Revenue (USD in millions)	Assumptions
2023	$10 – $15	Market stabilization, minor growth, increased hospital adoption
2024	$20 – $30	Expanded outpatient use, targeted marketing
2025	$35 – $50	Broader clinician acceptance, potential indication expansion
2026	$50 – $70	Further penetration, competitive positioning strengthened
2027	$70+	Peak market share, post-patent expiry of competitors

Revenue Drivers & Risks

• Drivers: Resistance trends favoring ZEMDRI, clinician acceptance, favorable reimbursement.
• Risks: Emergence of resistance to delafloxacin, policy changes, competition from future novel antibiotics.

---

6. Strategic Positioning and Market Opportunities

Opportunity	Actions	Challenges
Indication Expansion	Pursue approvals for urinary or intra-abdominal infections	Regulatory hurdles, clinical trial costs
Combination Therapies	Explore synergies with other antibiotics	Clinical validation required
Geographic Expansion	Enter European and Asian markets	Regulatory compliance, pricing policies
Supply Chain Optimization	Stabilize manufacturing to meet demand	Cost considerations

---

7. Deep-Dive Comparison: ZEMDRI vs. Major Competitors

Feature	ZEMDRI	Vancomycin	Linezolid	Levofloxacin
Spectrum	Broad, including resistant Gram-positives	Gram-positive only	Gram-positive, VRE	Gram-negative and positive
Route	IV and oral	IV	IV and oral	IV and oral
Pricing (Approx.)	$1,000+ per dose	~$20 per dose	~$200 per dose	~$3 per dose
Resistance Profile	Active against some resistant strains	Vulnerable	VRE resistance	Increasing resistance
Safety	Generally well tolerated; safety concerns exist	Nephrotoxicity	Hematologic toxicity	Tendinopathy, CNS effects

---

8. Future Outlook and Market Entrants

Key Factors Influencing ZEMDRI’s Market Trajectory

• Antibiotic Resistance Trends: Ongoing global AMR crisis pushes demand.
• Innovation & Regulation: Supportive policies for novel antibiotics.
• Competitive Innovation: Entry of new drugs or biosimilars could impact market share.

Potential Entrants

• Forthcoming antibiotics: SuroGuard, cadazolid, and others targeting resistant pathogens.
• Biosimilars/Generics: Not currently a threat for ZEMDRI but could emerge post-patent expiry.

---

9. Conclusion: Strategic Implications

ZEMDRI’s unique positioning as a potent, resistance-active fluoroquinolone offers a promising growth trajectory despite challenges. Its potential benefits in resistant SSTIs and pneumonia, combined with favorable pharmacokinetics, underpin its prospects. Success hinges on market penetration, indication expansion, and overcoming safety/prescription barriers.

---

10. Key Takeaways

• Market Niche: ZEMDRI is well-positioned in niche segments demanding efficacy against resistant bacteria, particularly MRSA.
• Revenue Potential: Estimated to grow from $10 million in 2023 to over $70 million by 2027, with upside if indications expand.
• Competitive Edge: Broad-spectrum activity and oral formulations favor outpatient therapy.
• Challenges: Competition from entrenched antibiotics, safety concerns, manufacturing stability, and regulatory hurdles.
• Strategic Focus: Expanding indications, geographic markets, and clinician awareness crucial for optimizing market share.

---

FAQs

1. What are the primary clinical advantages of ZEMDRI over other fluoroquinolones?

ZEMDRI offers enhanced activity against resistant pathogens such as MRSA, improved tissue penetration, efficacy in acidic environments, and a favorable safety profile compared to older fluoroquinolones.

2. How does resistance development impact ZEMDRI’s future market potential?

While currently effective, the emergence of resistance could limit long-term use. Continuous surveillance and stewardship are essential to preserve its utility and justify investment.

3. What regulatory opportunities exist for ZEMDRI’s broader application?

FDA designations like QIDP and Fast Track facilitate potential approval for additional indications such as urinary tract infections, expanding its market.

4. How does the pricing of ZEMDRI compare with its competitive set?

ZEMDRI’s cost (~$1,000 per dose) is significantly higher than generic fluoroquinolones but justified by its efficacy and resistance profile. Price pressures are expected to intensify with increased competition and biosimilar entries.

5. What are the key risks facing ZEMDRI’s market success?

Major risks include emerging resistance, safety concerns, manufacturing issues, and market competition from newer antibiotics or generics. Additionally, policy shifts toward antibiotic stewardship could restrain sales.

---

References

[1] World Health Organization. "Global Priority List of Antibiotic-Resistant Bacteria." 2019.
[2] Centers for Disease Control and Prevention. "Antibiotic Resistance Threats in the United States," 2019.